Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT

Huang, Genhua; Hu, Hui; Zhang, Yao; Zhu, Yinfang; Liu, Junli; Tan, Buzhen; Chen, Tingtao

doi:10.7150/jca.30669



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(13):3012-3020. doi:10.7150/jca.30669 This issue Cite

Research Paper

Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT

Genhua Huang¹, Hui Hu¹, Yao Zhang¹, Yinfang Zhu¹, Junli Liu¹, Buzhen Tan^1✉, Tingtao Chen^1,2✉

1. Department of Obstetrics & Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China
2. Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China

Citation:

Huang G, Hu H, Zhang Y, Zhu Y, Liu J, Tan B, Chen T. Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT. J Cancer 2019; 10(13):3012-3020. doi:10.7150/jca.30669. https://www.jcancer.org/v10p3012.htm

Other styles

Abstract

Advanced and chemotherapy-resistant ovarian cancer causes high mortality of ovarian cancer, and it is important to find safe and effective drugs to reduce the chemotherapeutic resistance of ovarian cancer. In our study, we attempted to clarify the resistance mechanisms of SKOV3/DDP cells in vitro and evaluated the sensitization to triptolide (TPL) in vivo. Our results indicated that the overexpression of AKT and p-AKT greatly enhanced the cisplatin (DDP) tolerance of SKOV3/DDP, and the combination of DDP+TPL had a significant tumour inhibition effect compared to DDP treatment (p<0.05), via reducing the expressions of p-PI3K, p-Akt, Survivin, VEGF and MMP-2, and the increase of Caspase-3. Collectively, these results suggest that the synergistic anticancer effect of TPL and DDP warrants their potential clinical applications in further.

Keywords: Triptolide, Cisplatin, PI3K/Akt, SKOV3/DDP, Sensitisation

Citation styles

APA

Huang, G., Hu, H., Zhang, Y., Zhu, Y., Liu, J., Tan, B., Chen, T. (2019). Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT. Journal of Cancer, 10(13), 3012-3020. https://doi.org/10.7150/jca.30669.

ACS

Huang, G.; Hu, H.; Zhang, Y.; Zhu, Y.; Liu, J.; Tan, B.; Chen, T. Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT. J. Cancer 2019, 10 (13), 3012-3020. DOI: 10.7150/jca.30669.

NLM

CSE

Huang G, Hu H, Zhang Y, Zhu Y, Liu J, Tan B, Chen T. 2019. Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT. J Cancer. 10(13):3012-3020.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.